medDream becomes part of the medavis Group and expands the portfolio with an innovative medical viewer

Footos: © medavis

Karlsruhe / June 26, 2024 – The medavis Group has signed a purchase agreement to acquire medDream. This strategic acquisition strengthens the portfolio with a universal medical zero-footprint viewer and represents an important milestone in the group's further internationalization.

The merger with medDream is a strategic step to strengthen the medavis Group's portfolio and thus further penetrate international markets. The powerful medDream Viewer plays a key role in this. It is universally applicable as a high-performance enterprise viewer in various medical disciplines. At the same time, it will become an integral component of the medavis referral and patient portal, thus supporting the entire treatment pathway for patients.

"Our goal is a perfect radiological workflow – from booking appointments to transmitting images and reports to referring physicians," says Michael Mauer, Chief Product Officer of the medavis Group. "This is where the new addition, medDream, fits perfectly as an innovative component focused on image management for reporting and presentation."

"We are proud to be part of the medavis Group and excited about the new opportunities this partnership opens up," explain medDream founders Tomas Dumbliauskas and Vytautas Baublys. "The resulting synergies will accelerate product development, expand cloud support, and increase added value for customers, OEMs, and distributors. Together with medavis, we can realize our vision of creating universal access to medical imaging and analytics, thus creating real added value for healthcare worldwide."

Thanks to the expertise of its experienced team in Kaunas, Lithuania, and its innovative product strategy, medDream is excellently positioned in the international OEM business and already works with more than 400 partners worldwide. The medDream Viewer is certified as a Class IIB medical device under the European Medical Device Regulation (MDR) and approved by the US FDA for diagnostic purposes. Certifications for other countries underscore the company's high quality and safety standards.